Breaking News, Collaborations & Alliances

AstraZeneca, WuXi Form Strategic Bio-alliance in China

Aims to expedite development of AZ's innovative biologics portfolio

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

WuXi AppTec has formed a strategic alliance with MedImmune, the global biologics R&D arm of AstraZeneca to bring research and technical capability for biologics to China to address unmet patient needs in AZ’s main therapy areas of respiratory, inflammation and autoimmunity; cardiovascular and metabolic diseases; and oncology. AZ will have the option to acquire WuXi’s biologics manufacturing facility in Wuxi city in the next few years. Prior to that, WuXi Biologics remains the ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters